Jupiter Neurosciences Raises $2M, Sells 7.14M Shares to Fund Parkinson’s Trial
Jupiter Neurosciences sold 7,142,858 shares in a registered direct offering to raise $2.0 million, using proceeds to pay down debt and bolster shareholder equity. The company said the financing extends cash runway for its Phase 2a JOTROL™ Parkinson’s trial and supports the planned PharmALA ALA-002 MDMA transaction.
1. Offering Details
On May 21, Jupiter Neurosciences closed a registered direct offering of 7,142,858 common shares, generating $2.0 million in gross proceeds from accredited investors.
2. Balance Sheet Improvement
Net proceeds were used to significantly reduce outstanding debt, strengthening the company’s equity position and simplifying its capital structure.
3. Parkinson’s Phase 2a Trial Funding
The new capital extends cash runway, enabling full execution of the Phase 2a JOTROL™ trial in Parkinson’s disease planned over the next year.
4. Progress on ALA-002 Acquisition
With a cleaner balance sheet, Jupiter is positioned to finalize its transaction with PharmALA for ALA-002 MDMA, bolstering its CNS pipeline.